Prostate cancer: Role of pretreatment MR in predicting outcome after external-beam radiation therapy - Initial experience

Radiology

Volumn 247, Issue 1, 2008, Pages 141-146

  McKenna, David A ^a   Coakley, Fergus V ^a   Westphalen, Antonio C ^a   Zhao, Shoujun ^c   Lu, Ying ^a   Webb, Emily M ^a   Pickett, Barby ^b   Roach III, Mack ^b   Kurhanewicz, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME; BONE TUMOR; BRACHYTHERAPY; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TUMOR RECURRENCE;

AGED; BONE NEOPLASMS; BRACHYTHERAPY; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 42449112495     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2471061982     Document Type: Article

References (25)

1. Huzjan R, Sala E, Hricak H. Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer. Nat Clin Pract Urol 2005;2(9):434-442.
2. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006;238(2):597-603.
3. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999;213(2):473-480.
4. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213(2):481-488.
5. Coakley FV, Qayyum A, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 2003;170(6 pt 2):S69-S75.
6. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002;223(1):91-97.
7. Dhingsa R, Qayyum A, Coakley FV, et al. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology 2004;230(1):215-220.
8. Schiebler ML, Yankaskas BC, Tempany C, et al. MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease. AJR Am J Roentgenol 1992;158(3):559-562.
9. Clarke DH, Banks SJ, Wiederhorn AR, et al. The role of endorectal coil MRI in patient selection and treatment planning for prostate seed implants. Int J Radiat Oncol Biol Phys 2002;52(4):903-910.
10. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997;202(3):697-702.
11. Fütterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005;237(2):541-549.
12. American Joint Committee on Cancer. Prostate. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC cancer staging manual. 6th ed. New York, NY: Springer, 2002; 309-316.
13. Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma. Cancer 1999;85(12):2630-2637.
14. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006;65(4):965-974.
15. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-174.
16. Kuban DA, Thames HD, Shipley WU. Defining recurrence after radiation for prostate cancer. J Urol 2005;173(6):1871-1878.
17. Pickles T, Pollack A. The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer. Can J Urol 2006;13(suppl 2):68-71.
18. Jager GJ, Ruijter ET, van de Kaa CA, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol 1996;166(4):845-852.
19. D'Amico AV, Whittington R, Malkowicz B, et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000;164(3 pt 1):759-763.
20. Hricak H, Wang L, Wei DC, et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004;100(12):2655-2663.
21. Fuks Z, Leibel SA, Wallner KE, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 1991;21(3):537-547.
22. Yorke ED, Fuks Z, Norton L, Whitmore W, Ling CC. Modeling the development of metastases from primary and locally recurrent tumours: comparison with a clinical data base for prostatic cancer. Cancer Res 1993;53(13):2987-2993.
23. Stromberg J, Martinez A, Benson R, et al. Improved local control and survival for surgically staged patients with locally advanced prostate cancer treatment with up-front low dose rate iridium-192 prostate implantation and external beam irradiation. Int J Radiat Oncol Biol Phys 1994;28(1):67-75.
24. D'Amico AV, Whittington R, Malkowicz SB, et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol 1996;14(6):1770-1777.
25. D'Amico AV, Whittington R, Malkowicz SB, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154(1):131-138.